Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review
(Source: Core Evidence)
Source: Core Evidence - February 11, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review
Joumana Kmeid, Zeina A Kanafani Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon Abstract: The emergence of resistance to glycopeptide antibiotics such as vancomycin and teicoplanin among Gram-positive bacteria has spurred the search for second-generation drugs of this class. Oritavancin, a promising novel, second-generation, semisynthetic lipoglycopeptide, is distinguished by two mechanisms of action: inhibition of cell wall synthesis and disruption of the cell membrane. This dual mechanism of action has increased the activity of oritavancin a...
Source: Core Evidence - February 11, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Oritavancin for acute bacterial skin and skin structure infections
Kmeid J, Kanafani ZA (Source: Core Evidence)
Source: Core Evidence - February 10, 2015 Category: Drugs & Pharmacology Source Type: research
Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - January 12, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy
Jennifer Dinnel,1 Bonny L Moore,1 Brent M Skiver,1 Prithviraj Bose1,2 1Department of Internal Medicine, Virginia Commonwealth University, 2VCU Massey Cancer Center, Richmond, VA, USA Abstract: Tumor lysis syndrome (TLS) is a potentially life-threatening complication of cancer therapy characterized by two or more of the following laboratory abnormalities: hyperuricemia, hyperkalemia, hypocalcemia, and hyperphosphatemia, with resultant end-organ damage, eg, renal failure, seizures, or cardiac arrhythmias. High-risk patients include those with highly proliferative cancers and/or large tumor burdens, particularly in the setti...
Source: Core Evidence - January 12, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Rasburicase in the management of tumor lysis
Dinnel J, Moore BL, Skiver BM, Bose P (Source: Core Evidence)
Source: Core Evidence - January 12, 2015 Category: Drugs & Pharmacology Source Type: research
Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
(Source: Core Evidence)
Source: Core Evidence - January 9, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
Conclusion: Dulaglutide is a once-weekly GLP-1 RA approved for the treatment of T2DM that has shown similar efficacy to other agents in this class. Keywords: GLP-1 RA, glucagon-like peptide-1 receptor agonist, incretin mimetic, type 2 diabetes mellitus therapy (Source: Core Evidence)
Source: Core Evidence - January 9, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Dulaglutide use in type 2 diabetes mellitus
Edwards KL, Minze MG (Source: Core Evidence)
Source: Core Evidence - January 8, 2015 Category: Drugs & Pharmacology Source Type: research
Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - December 18, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
Julie N Graff,1,2 Erin D Chamberlain31Portland VA Medical Center, 2Knight Cancer Institute, 3Department of Medicine, Oregon Health and Science University, Portland, OR, USAAbstract: Metastatic castration-resistant prostate cancer is the lethal form of cancer of the prostate. Five new agents that prolong survival in this group have emerged in the past 5 years, and sipuleucel-T is among them. Sipuleucel-T is the only immunotherapy shown to improve survival in prostate cancer. It is currently indicated in asymptomatic or mildly symptomatic patients, as it has never shown a direct cancer effect. This paper describes the proces...
Source: Core Evidence - December 18, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Sipuleucel-T in prostate cancer
Graff JN, Chamberlain ED (Source: Core Evidence)
Source: Core Evidence - December 17, 2014 Category: Drugs & Pharmacology Source Type: research
